Background:
Aggressive B-cell lymphoma is a highly heterogeneous group of tumors, with a cure rate of less than 50% in high-risk patients undergoing treatment with the R-CHOP regimen. Multiple studies have indicated promising efficacy for dose-enhanced immunochemotherapy in high-risk patients. Few studies on aggressive B-cell lymphoma have prospectively explored treatment strategy modifications guided by interim positron emission tomography (PET) responses. To address this gap, we conducted a prospective, multicenter, single-arm, phase 2 trial to evaluate the efficacy and safety of response-driven dose-intensified immunochemotherapy with or without autologous stem cell transplantation (ASCT) in young previously untreated patients with high-risk aggressive B-cell lymphoma.
Methods:
Eligible patients for the DLCL002 protocol were previously untreated individuals aged 18 to 65 years, diagnosed with high-risk aggressive B-cell lymphoma, as defined by an International Prognostic Index (IPI) score of 3 to 5 or an age-adjusted IPI (aaIPI) score of 2 to 3, double protein expression lymphoma (immunohistochemistry MYC≥40% and BCL2≥50%) with Ann Arbor stage of III-IV or aaIPI 2-3 or IPI 3-5, or CD5 positivity. Additionally, patients with high-grade B-cell lymphomas (HGBCL) characterized by MYC and BCL2 and/or BCL6 rearrangements, as well as those with HGBCL not otherwise specified (NOS) or transformed lymphoma, were included. Patients received 4 cycles of R-DA-EDOCH chemotherapy (Rituximab, Etoposide, Vincristine, Doxorubicin, Dexamethasone, Cyclophosphamide). Efficacy was evaluated using PET-CT imaging following the completion of these four cycles. Those who achieved a partial response (PR), as indicated by a Deauville score of 4-5, subsequently received two cycles of R(X)-DHAP salvage chemotherapy. At the discretion of the treating clinician, patients could undergo ASCT. The primary endpoint of the study was the 2-year progression-free survival (PFS) rate.
Results:
Between January 2019 and August 2023, a total of 107 patients were enrolled, with a median age of 54 years. Of these, 100 patients (93.5%) presented with Ann Arbor stage III-IV disease, and 89 patients (83.2%) had an IPI score of 3-5 or an aaIPI score of 2-3. A total of 104 patients (97.2%) received between 4 and 8 cycles of induction therapy. At the time of the interim evaluation, 106 patients were assessable for efficacy. The complete response (CR) rate and overall response rate (ORR) were 79.2% (95% confidence interval [CI]: 70.6, 85.9) and 94.3% (95% CI: 88.2, 97.4), respectively. Eight patients who achieved a PR subsequently adjusted their treatment regimen to R(X)-DHAP. Following this adjustment, the CR rate and ORR were 83.0% (95% CI: 74.8, 89.0) and 88.7% (95% CI: 81.3, 93.4), respectively. Subsequently, 45 patients (42%) underwent ASCT after immunochemotherapy. At the end of treatment, the ORR remained at 88.7%, while the CR rate increased to 87.7% (95% CI: 80.2, 92.7).
At the data cut-off date of April 1, 2024, the median follow-up was 32.9 months (range: 5-64 months), and the median PFS and overall survival (OS) were not reached. The 2-year PFS and OS rates were 78.2% (95% CI: 70.2, 86.2) and 86.7% (95% CI: 80.0, 93.4), respectively. The predominant adverse events (AEs) associated with the treatment were hematologic toxicities. Grade 3/4 AEs observed in ≥10% of patients included neutropenia, anemia, thrombocytopenia, and pulmonary infection.
Conclusions:
Response-driven, dose-enhanced immunochemotherapy, with or without ASCT, demonstrated promising long-term outcomes and was well tolerated in young, previously untreated patients with high-risk aggressive B-cell lymphoma. This therapeutic strategy warrants further clinical investigation.
No relevant conflicts of interest to declare.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal